36101495|t|The signaling and selectivity of alpha-adrenoceptor agonists for the human alpha2A, alpha2B and alpha2C-adrenoceptors and comparison with human alpha1 and beta-adrenoceptors.
36101495|a|alpha2-adrenoceptors, (alpha2A, alpha2B and alpha2C-subtypes), are Gi-coupled receptors. Central activation of brain alpha2A and alpha2C-adrenoceptors is the main site for alpha2-agonist mediated clinical responses in hypertension, ADHD, muscle spasm and ITU management of sedation, reduction in opiate requirements, nausea and delirium. However, despite having the same Gi-potency in functional assays, some alpha2-agonists also stimulate Gs-responses whilst others do not. This was investigated. Agonist responses to 49 different alpha-agonists were studied (CRE-gene transcription, cAMP, ERK1/2-phosphorylation and binding affinity) in CHO cells stably expressing the human alpha2A, alpha2B or alpha2C-adrenoceptor, enabling ligand intrinsic efficacy to be determined (binding KD /Gi-IC50 ). Ligands with high intrinsic efficacy (e.g., brimonidine and moxonidine at alpha2A) stimulated biphasic (Gi-Gs) concentration responses, however for ligands with low intrinsic efficacy (e.g., naphazoline), responses were monophasic (Gi-only). ERK1/2-phosphorylation responses appeared to be Gi-mediated. For Gs-mediated responses to be observed, both a system with high receptor reserve and high agonist intrinsic efficacy were required. From the Gi-mediated efficacy ratio, the degree of Gs-coupling could be predicted. The clinical relevance and precise receptor conformational changes that occur, given the structural diversity of compounds with high intrinsic efficacy, remains to be determined. Comparison with alpha1 and beta1/beta2-adrenoceptors demonstrated subclass affinity selectivity for some compounds (e.g., alpha2:dexmedetomidine, alpha1:A61603) whilst e.g., oxymetazoline had high affinity for both alpha2A and alpha1A-subtypes, compared to all others. Some compounds had subclass selectivity due to selective intrinsic efficacy (e.g., alpha2:brimonidine, alpha1:methoxamine/etilefrine). A detailed knowledge of these agonist characteristics is vital for improving computer-based deep-learning and drug design.
36101495	69	74	human	Species	9606
36101495	75	83	alpha2A,	Gene	28882
36101495	84	91	alpha2B	Gene	151
36101495	138	143	human	Species	9606
36101495	198	206	alpha2A,	Gene	28882
36101495	207	214	alpha2B	Gene	151
36101495	219	226	alpha2C	Gene	28882
36101495	292	325	alpha2A and alpha2C-adrenoceptors	Gene	150;152
36101495	347	353	alpha2	Gene	170589
36101495	393	405	hypertension	Disease	MESH:D006973
36101495	407	411	ADHD	Disease	MESH:D001289
36101495	413	425	muscle spasm	Disease	MESH:D013035
36101495	471	477	opiate	Chemical	MESH:D053610
36101495	492	498	nausea	Disease	MESH:D009325
36101495	503	511	delirium	Disease	MESH:D003693
36101495	546	548	Gi	Gene	2770
36101495	584	591	alpha2-	Gene	170589
36101495	760	764	cAMP	Chemical	-
36101495	766	772	ERK1/2	Gene	5595;5594
36101495	814	817	CHO	CellLine	CVCL:0213
36101495	846	851	human	Species	9606
36101495	852	860	alpha2A,	Gene	28882
36101495	861	868	alpha2B	Gene	151
36101495	872	892	alpha2C-adrenoceptor	Gene	152
36101495	959	961	Gi	Gene	2770
36101495	1014	1025	brimonidine	Chemical	MESH:D000068438
36101495	1030	1040	moxonidine	Chemical	MESH:C043482
36101495	1044	1051	alpha2A	Gene	28882
36101495	1074	1076	Gi	Gene	2770
36101495	1161	1172	naphazoline	Chemical	MESH:D009278
36101495	1202	1204	Gi	Gene	2770
36101495	1212	1218	ERK1/2	Gene	5595;5594
36101495	1260	1262	Gi	Gene	2770
36101495	1416	1418	Gi	Gene	2770
36101495	1685	1721	alpha1 and beta1/beta2-adrenoceptors	Gene	153;154
36101495	1791	1797	alpha2	Gene	170589
36101495	1798	1813	dexmedetomidine	Chemical	MESH:D020927
36101495	1815	1822	alpha1:	Gene	597
36101495	1822	1828	A61603	Chemical	MESH:C094643
36101495	1843	1856	oxymetazoline	Chemical	MESH:D010109
36101495	1884	1891	alpha2A	Gene	28882
36101495	1896	1903	alpha1A	Gene	5265
36101495	2021	2027	alpha2	Gene	170589
36101495	2028	2039	brimonidine	Chemical	MESH:D000068438
36101495	2041	2047	alpha1	Gene	597
36101495	2048	2059	methoxamine	Chemical	MESH:D008729
36101495	2060	2070	etilefrine	Chemical	MESH:D005039
36101495	Association	MESH:D009325	152
36101495	Association	MESH:D000068438	2770
36101495	Association	MESH:D001289	150
36101495	Association	MESH:D001289	152
36101495	Association	MESH:D010109	5265
36101495	Association	MESH:D009325	150
36101495	Association	MESH:C043482	28882
36101495	Association	MESH:D013035	150
36101495	Association	MESH:D013035	152
36101495	Association	MESH:D006973	170589
36101495	Association	MESH:D009325	170589
36101495	Association	2770	5594
36101495	Association	MESH:D003693	150
36101495	Association	MESH:D053610	150
36101495	Association	MESH:D003693	152
36101495	Association	MESH:D001289	170589
36101495	Association	MESH:D003693	170589
36101495	Positive_Correlation	MESH:D013035	170589
36101495	Association	MESH:D003693	28882
36101495	Association	MESH:C043482	2770
36101495	Association	MESH:D006973	150
36101495	Association	2770	5595
36101495	Association	MESH:D010109	28882
36101495	Association	MESH:D053610	152
36101495	Association	MESH:D006973	152

